Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

TABLE 2

Metabolic parameters from IVGTTs at baseline and 3 months on trial

Placebo group (n = 109)
Troglitazone group (n = 108)
Baseline 3 months P Baseline 3 months P
Fasting glucose (mg/dl) 94.3 ± 10.4 97.2 ± 14.5 0.009 94.5 ± 10.0 91.0 ± 10.4 <0.0001
Kg (min−1 × 100) 1.49 ± 0.40 1.48 ± 0.41 0.99 1.43 ± 0.41 1.46 ± 0.48 0.53
SI (min−1 per μU/ml × 10−4) 2.34 ± 1.80 2.17 ± 1.48 0.17 2.60 ± 1.67 3.76 ± 2.27 <0.0001
Insulin area (μU/ml × min) 10518 ± 5,544 10701 ± 5,673 0.90 9,402 ± 5,504 6,551 ± 3,644 <0.0001
AIRg (μU/ml × min) 542 ± 499 534 ± 460 0.91 461 ± 357 406 ± 294 0.10
DI 995 ± 709 969 ± 720 0.35 987 ± 720 1321 ± 852 <0.0001
  • Data are means ± SD from all women who had IVGTTs at both times. P values are for difference from zero of change in each group between baseline and 3 months, by Wilcoxon’s signed-rank test.

This Article

  1. Diabetes vol. 51 no. 9 2796-2803